Companies › Servier Bio-Innovation
6 active drug programs in 8 registered trials: 7 Phase 1, 1 Phase 3; Oncology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ivosidenib Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor | IDH1 | Phase 3 | Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen; IDH1-Mutated Malignancies | Feb 2028 |
| S095018 Anti-TIM3 antibody | HAVCR2 | Phase 1 | Non-small Cell Lung Cancer (NSCLC) | Apr 2027 |
| S095024 Anti-CD73 antibody | NT5E | Phase 1 | Non-small Cell Lung Cancer (NSCLC) | Apr 2027 |
| S095029 | – | Phase 1 | Non-small Cell Lung Cancer (NSCLC); MSI-H/dMMR Gastroesophageal-junction Cancer | Apr 2027 |
| S095035 MAT2A inhibitor | MAT2A | Phase 1 | MTAP-deleted Solid Tumors | May 2027 |
| TNG462 PRMT5 inhibitor | PRMT5 | Phase 1 | MTAP-deleted Solid Tumors | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06162572 | S095018 | Phase 1 | Non-small Cell Lung Cancer (NSCLC) | Oncology | Apr 2027 |
| NCT06162572 | S095024 | Phase 1 | Non-small Cell Lung Cancer (NSCLC) | Oncology | Apr 2027 |
| NCT06162572 | S095029 | Phase 1 | Non-small Cell Lung Cancer (NSCLC) | Oncology | Apr 2027 |
| NCT06188702 | S095035 | Phase 1 | MTAP-deleted Solid Tumors | Oncology | May 2027 |
| NCT06188702 | TNG462 | Phase 1 | MTAP-deleted Solid Tumors | Oncology | May 2027 |
| NCT06116136 | S095029 | Phase 1 | MSI-H/dMMR Gastroesophageal-junction Cancer | Oncology | Aug 2027 |
| NCT06127407 | Ivosidenib | Phase 3 | Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen | Oncology | Feb 2028 |
| NCT07006688 | Ivosidenib | Phase 1 | IDH1-Mutated Malignancies | Oncology | Jul 2028 |
AstraZeneca Bristol-Myers Squibb Servier Novartis Akeso IDEAYA Biosciences Tango Therapeutics Eli Lilly Nuvation Bio Kissei Pharmaceutical
IDEAYA Biosciences MediLink Therapeutics (Suzhou) LaNova Medicines Kumquat Biosciences GI Innovation
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.